Maxcyte Stock Working Capital
MaxCyte fundamentals help investors to digest information that contributes to MaxCyte's financial success or failures. It also enables traders to predict the movement of MaxCyte Stock. The fundamental analysis module provides a way to measure MaxCyte's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to MaxCyte stock.
MaxCyte |
MaxCyte Company Working Capital Analysis
MaxCyte's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current MaxCyte Working Capital | 172.34 M |
Most of MaxCyte's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, MaxCyte is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
CompetitionBased on the company's disclosures, MaxCyte has a Working Capital of 172.34 M. This is 59.51% lower than that of the Health Care Equipment & Supplies sector and 87.34% lower than that of the Health Care industry. The working capital for all United States stocks is 88.34% higher than that of the company.
MaxCyte Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses MaxCyte's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of MaxCyte could also be used in its relative valuation, which is a method of valuing MaxCyte by comparing valuation metrics of similar companies.MaxCyte is currently under evaluation in working capital category among its peers.
MaxCyte Fundamentals
| Return On Equity | -0.15 | ||||
| Return On Asset | -0.11 | ||||
| Profit Margin | (0.83) % | ||||
| Operating Margin | (1.08) % | ||||
| Current Valuation | 379.67 M | ||||
| Shares Outstanding | 104.54 M | ||||
| Shares Owned By Insiders | 1.21 % | ||||
| Shares Owned By Institutions | 74.80 % | ||||
| Number Of Shares Shorted | 3.69 M | ||||
| Price To Book | 2.06 X | ||||
| Price To Sales | 11.20 X | ||||
| Revenue | 41.29 M | ||||
| Gross Profit | 39.16 M | ||||
| EBITDA | (44.04 M) | ||||
| Net Income | (37.92 M) | ||||
| Cash And Equivalents | 240.89 M | ||||
| Cash Per Share | 2.37 X | ||||
| Total Debt | 18.74 M | ||||
| Debt To Equity | 0.06 % | ||||
| Current Ratio | 14.24 X | ||||
| Book Value Per Share | 2.17 X | ||||
| Cash Flow From Operations | (21.69 M) | ||||
| Short Ratio | 5.92 X | ||||
| Earnings Per Share | (0.35) X | ||||
| Target Price | 9.25 | ||||
| Number Of Employees | 143 | ||||
| Beta | 1.08 | ||||
| Market Capitalization | 518.54 M | ||||
| Total Asset | 268.27 M | ||||
| Retained Earnings | (175.8 M) | ||||
| Working Capital | 172.34 M | ||||
| Net Asset | 268.27 M |
Pair Trading with MaxCyte
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if MaxCyte position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in MaxCyte will appreciate offsetting losses from the drop in the long position's value.Moving against MaxCyte Stock
| 0.66 | FNA | Paragon 28 | PairCorr |
| 0.52 | NXL | Nexalin Technology Buyout Trend | PairCorr |
| 0.47 | VMD | Viemed Healthcare | PairCorr |
| 0.32 | PEN | Penumbra | PairCorr |
The ability to find closely correlated positions to MaxCyte could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace MaxCyte when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back MaxCyte - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling MaxCyte to buy it.
The correlation of MaxCyte is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as MaxCyte moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if MaxCyte moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for MaxCyte can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for MaxCyte Stock Analysis
When running MaxCyte's price analysis, check to measure MaxCyte's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MaxCyte is operating at the current time. Most of MaxCyte's value examination focuses on studying past and present price action to predict the probability of MaxCyte's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MaxCyte's price. Additionally, you may evaluate how the addition of MaxCyte to your portfolios can decrease your overall portfolio volatility.